Ravindranathan, Sruthi http://orcid.org/0000-0003-0451-7931
Passang, Tenzin http://orcid.org/0000-0003-3393-8161
Li, Jian-Ming http://orcid.org/0000-0001-6368-759X
Wang, Shuhua
Dhamsania, Rohan http://orcid.org/0000-0003-3049-1704
Ware, Michael Brandon
Zaidi, Mohammad Y.
Zhu, Jingru
Cardenas, Maria http://orcid.org/0000-0002-8566-9576
Liu, Yuan http://orcid.org/0000-0001-8926-3058
Gumber, Sanjeev
Robinson, Brian
Sen-Majumdar, Anish
Zhang, Hanwen http://orcid.org/0000-0001-8955-7494
Chandrakasan, Shanmuganathan http://orcid.org/0000-0001-8007-9932
Kissick, Haydn http://orcid.org/0000-0001-7624-5598
Frey, Alan B.
Thomas, Susan N. http://orcid.org/0000-0003-4651-232X
El-Rayes, Bassel F.
Lesinski, Gregory B. http://orcid.org/0000-0002-8787-7678
Waller, Edmund K. http://orcid.org/0000-0003-0816-6729
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (NIH R01 CA207619)
Katz Foundation funding Emory School of Medicine Dean’s Imagine, Innovate and Impact (I3) venture award
Emory University | Winship Cancer Institute
Emory University | School of Medicine, Emory University
Abraham and J. Phyllis Katz Foundation Adaptive Biotechnologies Rein Saral Professorship in Cancer Medicine
Article History
Received: 19 August 2021
Accepted: 18 October 2022
First Online: 27 October 2022
Competing interests
: Intellectual property related to the use of peptide antagonists to vasoactive intestinal polypeptides to treat cancer is the subject of US patent applications with S.R., T.P., J.M.L., A.S.M., S.N.T., and E.K.W. listed as inventors. These patents have been licensed to Cambium Oncology, LLC. E.K.W., S.N.T., and S.C. are co-founders and have equity in Cambium Oncology. A.S.M. is a former employee of Cambium Oncology. A.B.F. is a current employee of Cambium Oncology. A conflict-of-interest management plan has been reviewed and approved by Emory University. The remaining authors declare no competing interests.